393 related articles for article (PubMed ID: 30277471)
21. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
22. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
[TBL] [Abstract][Full Text] [Related]
23. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
24. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Qorraj M; Bruns H; Böttcher M; Weigand L; Saul D; Mackensen A; Jitschin R; Mougiakakos D
Leukemia; 2017 Feb; 31(2):470-478. PubMed ID: 27479178
[TBL] [Abstract][Full Text] [Related]
25. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
[TBL] [Abstract][Full Text] [Related]
26. Frequency and functional characterization of exhausted CD8
Taghiloo S; Allahmoradi E; Tehrani M; Hossein-Nataj H; Shekarriz R; Janbabaei G; Abediankenari S; Asgarian-Omran H
Eur J Haematol; 2017 Jun; 98(6):622-631. PubMed ID: 28306177
[TBL] [Abstract][Full Text] [Related]
27. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
28. CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia.
Allahmoradi E; Taghiloo S; Tehrani M; Hossein-Nattaj H; Janbabaei G; Shekarriz R; Asgarian-Omran H
Iran J Immunol; 2017 Dec; 14(4):257-269. PubMed ID: 29276179
[TBL] [Abstract][Full Text] [Related]
29. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
30. CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.
Cuenca M; Sintes J; Lányi Á; Engel P
Clin Immunol; 2019 Jul; 204():43-49. PubMed ID: 30522694
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
[TBL] [Abstract][Full Text] [Related]
32. TBET-expressing Th1 CD4
Roessner PM; Hanna BS; Öztürk S; Schulz R; Llaó Cid L; Yazdanparast H; Scheffold A; Colomer D; Stilgenbauer S; Lichter P; Seiffert M
Br J Haematol; 2020 Apr; 189(1):133-145. PubMed ID: 31724172
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.
Bürgler S; Gimeno A; Parente-Ribes A; Wang D; Os A; Devereux S; Jebsen P; Bogen B; Tjønnfjord GE; Munthe LA
J Immunol; 2015 Jan; 194(2):827-35. PubMed ID: 25505279
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
35. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
36. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.
Banerjee P; Zhang R; Ivan C; Galletti G; Clise-Dwyer K; Barbaglio F; Scarfò L; Aracil M; Klein C; Wierda W; Plunkett W; Caligaris-Cappio F; Gandhi V; Keating MJ; Bertilaccio MTS
Cancer Immunol Res; 2019 Dec; 7(12):2036-2051. PubMed ID: 31530560
[TBL] [Abstract][Full Text] [Related]
38. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
[TBL] [Abstract][Full Text] [Related]
39. PD-1 /PD-L1 checkpoint in hematological malignancies.
Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
[TBL] [Abstract][Full Text] [Related]
40. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
